Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers

 
• By Ian Haydock, Jung Won Shin, and Joseph Haas

Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.

Intravascular non Hodgkins lymphoma - Image
Ambrx, NovoCodex are partnering on an ADC for hematologic cancers including NHL

More from Deals

More from Business